Contact this trialFirst, we need to learn more about you.
ADG126 + Pembrolizumab for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a combination of two drugs, ADG126 and Pembrolizumab, in patients with advanced or metastatic solid tumors. ADG126 helps activate immune cells to attack cancer by targeting a specific protein. Pembrolizumab boosts the immune response by blocking another protein that usually stops immune cells from attacking cancer. The goal is to see if this combination is safe and effective for these patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service